This fated transformation of a HR precursor cell to a HR+/- tumor subtype is not due to the mutations or amplifications in the genes coding for HR proteins (ER, AR or VDR), which are relatively rare events in breast cancer [27]. This evidence concerns the gene ESR1 and breast carcinoma.